CTMC, a joint venture between MD Anderson Cancer Center and Resilience, has entered a partnership with Syenex to advance the scalability and efficiency of engineered T cell therapies. Through this collaboration, CTMC will gain access to Syenex’s bioengineering systems, which provide a significant improvement in gene delivery efficiency and engineering timelines. The partnership aims to leverage the most advanced tools and technologies to streamline manufacturing and clinical translation.